ITRM's free cash flow for Q2 2023 was $-7.65M. For the 2023 fiscal year, ITRM's free cash flow was decreased by $-1.55M and operating cash flow was $-7.63M. See a summary of the company’s cash flow.

Cash Flow	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Operating Cash Flow	$ -26.03M	$ -18.47M	$ -16.92M	$ -54.53M	$ -81.92M	$ -77.25M
Investing Cash Flow	$ 29.68M	$ 13.96M	$ -54.59M	$ -11.00K	$ 40.10M	$ -8.66M
Financing Cash Flow	$ 868.00K	$ -1.82M	$ 83.13M	$ 64.47M	$ 2.06M	$ 122.20M
Cash Flow From Discontinued Operation	-	-	-	-	-	-
Other Cash Adjustment Inside Changein Cash	-	-	-	-	-	-
End Cash Position	$ 72.20M	$ 21.13M	$ 26.43M	$ 14.82M	$ 4.89M	$ 44.67M
Income Tax Paid Supplemental Data	$ -66.00K	$ 821.00K	$ 435.00K	$ 120.00K	$ 414.00K	$ 352.00K
Interest Paid Supplemental Data	-	$ 22.00K	$ 416.00K	$ 996.00K	$ 1.40M	$ 809.00K
Issuance Of Capital Stock	$ 868.00K	$ 433.00K	$ 89.64M	$ 69.96M	$ 3.04M	$ 107.69M
Issuance Of Debt	-	$ -2.25M	$ -6.52M	$ 744.00K	$ 0.00	$ 14.51M
Repayment Of Debt	-	$ -2.25M	$ -6.52M	$ -6.23M	$ -1.03M	$ 0.00
Free Cash Flow	$ -26.09M	$ -18.54M	$ -16.98M	$ -54.54M	$ -81.95M	$ -77.34M
Domestic Sales	-	-	-	-	-	-
Foreign Sales	-	-	-	-	-	-

Currency in USD

Iterum Therapeutics Cash Flow

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing